Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Sponsor: Eli Lilly and Company
Summary
The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Participation in the study will last up to approximately 52 weeks.
Official title: A Phase 1, Multicenter, Randomized, Placebo-Controlled, Participant-Blind, Single-Ascending Dose Study of LY4298445 in Healthy Participants and an Open-Label Single-Ascending Dose and Multiple-Ascending Dose Study of LY4298445 in Participants With Systemic Lupus Erythematosus or Rheumatoid Arthritis
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
63
Start Date
2026-02-04
Completion Date
2028-03
Last Updated
2026-03-23
Healthy Volunteers
Yes
Interventions
LY4298445
Administered SC
LY4298445
Administered IV
Locations (7)
Nucleus Network
Brisbane, Australia
Nucleus Network
Melbourne, Australia
Peking University First Hospital
Beijing, China
Peking University Third Hospital
Beijing, China
Xiangya Hospital of Central South University
Changsha, China
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China